Stem Cell Researchers Take on Parkinson's

Parkinson's disease could be the perfect target for stem cell therapy. The etiology of this progressively debilitating disease is clear: scientists know what cells are affected, where those cells reside, when those cells are created during development, and what their target is. This information is reported in scores of articles on cell transplantation that use fetal cells to treat Parkinson's in animal models and people. The good news continues. New research shows that by using stem cells, sci

Written byLaura Defrancesco
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The good news continues. New research shows that by using stem cells, scientists can produce an unlimited supply of dopamine (DA) neurons,1,2 the same neurons that inexplicably die off in Parkinson's patients. (Dopamine is the chemical that helps direct muscle activity.) Scientists at Rockefeller University and Memorial Sloan-Kettering Cancer Center recently reported that they produced DA neurons from adult somatic cells using "Dolly-esque" cloning technology.3 This finding raises the possibility that one day, therapeutic cloning could help generate DA neurons from a patient's own tissue, eliminating the worry that the tissue will be rejected and freeing transplant patients from having to take powerful immunosuppressive drugs.

Now the down side: Numerous issues jeopardize continued stem cell research. The current political posture regarding research on embryonic stem cells, a troublesome and well-publicized clinical trial that has caused some to question whether cell therapy should even be done with people, and lots of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies